Immunomedics Reports Progress With Milatuzumab at 52nd ASH Annual Meeting

ORLANDO, Fla., Dec. 5, 2010 (GLOBE NEWSWIRE) — Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that combination treatment with milatuzumab, the first humanized anti-CD74 antibody in clinical testing, and veltuzumab, a second-generation humanized anti-CD20 [...] http://bit.ly/dMUnSt